VPM1002 对比卡介苗在南非新生儿中的安全性与免疫原性:一项随机、2 期非劣效性双盲对照试验
在南非四家健康中心开展的随机双盲 2 期非劣效性试验中,416 名新生儿按 3:1 随机接受 VPM1002 或卡介苗(BCG)。VPM1002 组 3–4 级疫苗相关不良反应或直径≥10 mm 淋巴结病的发生率为 2%,BCG 组为 33%,VPM1002 对 BCG 非劣效;VPM1002 反应原性更低,但免疫原性应答低于 BCG。
要点
- VPM1002 组 3–4 级疫苗相关不良反应或≥10 mm 淋巴结病发生率 2%,BCG 组 33%,非劣效成立。
- VPM1002 组严重注射部位反应(瘢痕、溃疡、脓肿)发生率均低于 BCG 组。
- 两种疫苗均有免疫原性,但 BCG 组的 IFNγ 和多功能 T 细胞应答总体更高。
核心结论
- VPM1002 的反应原性低于 BCG,且未发现严重安全性问题;两种疫苗均有免疫原性,但 BCG 的免疫应答更高。
- VPM1002 目前正在撒哈拉以南非洲婴儿中开展多中心 3 期临床研究以评估有效性和安全性。
研究设计与样本
- 双盲、随机、阳性对照 2 期研究,在南非四家健康中心开展。
- 纳入年龄≤12 天、出生体重 2.5–4.2 kg 的新生儿,可为 HIV 暴露(母亲血清阳性)或非暴露(母亲血清阴性)。
- 416 名合格新生儿按 3:1 随机分配至 VPM1002 组或 BCG 组,按 HIV 状态分层,区组大小为 8。
- 主要结局为 12 个月内 3–4 级药物不良反应或同侧或全身直径≥10 mm 淋巴结病的发生率,非劣效界值 15%。
- 次要免疫原性结局为 12 个月研究期间干扰素-γ 水平及多功能 CD4+ 和 CD8+ T 细胞占全部淋巴细胞百分比。
主要发现
- VPM1002 组 312 名参与者中 7 名(2%)出现 3–4 级疫苗相关不良反应或直径≥10 mm 淋巴结病,BCG 组 104 名中 34 名(33%)出现,风险差 -30.45%(95%CI -39.61% 至 -21.28%),非劣效性 p<0.0001。
- 瘢痕发生于 VPM1002 组 65 名(21%)参与者 vs BCG 组 77 名(74%)参与者(p<0.0001)。
- 溃疡发生于 VPM1002 组 1 名(<1%)vs BCG 组 15 名(14%)(p<0.0001);脓肿形成发生于 VPM1002 组 5 名(2%)vs BCG 组 23 名(22%)(p<0.0001)。
- 再刺激 IFNγ 浓度在第 6 周、第 12 周、第 6 个月和第 12 个月时 VPM1002 组低于 BCG 组。
- 多功能 CD4+ T 细胞百分比在第 14 天时 VPM1002 组高于 BCG 组,但在第 6 周、第 12 周、第 6 个月和第 12 个月时低于 BCG 组;多功能 CD8+ T 细胞百分比在第 6 周、第 12 周和第 6 个月时 VPM1002 组低于 BCG 组,其他时间点无差异。
关键数值与推荐
- 主要结局非劣效界值为 15%。
- VPM1002 组 3–4 级疫苗相关不良反应或≥10 mm 淋巴结病 7/312(2%)vs BCG 组 34/104(33%),风险差 -30.45%(95%CI -39.61% 至 -21.28%),非劣效性 p<0.0001。
- 瘢痕 65/312(21%)vs 77/104(74%),p<0.0001;溃疡 1/312(<1%)vs 15/104(14%),p<0.0001;脓肿 5/312(2%)vs 23/104(22%),p<0.0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis is a major public health problem worldwide. Immunisation with Mycobacterium bovis BCG vaccine is partially effective in infants, reducing the incidence of miliary and tuberculosis meningitis, but is less effective against pulmonary tuberculosis. We aimed to compare safety and immunogenicity of VPM1002-a recombinant BCG vaccine developed to address this gap-with BCG in HIV exposed and HIV unexposed newborn babies. METHODS: This double-blind, randomised, active controlled phase 2 study was conducted at four health centres in South Africa. Eligible neonates were aged 12 days or younger with a birthweight of 2·5-4·2 kg, and could be HIV exposed (seropositive mothers) or unexposed (seronegative mothers). Newborn babies were excluded if they had acute or chronic illness, fever, hypothermia, sepsis, cancer, or congenital malformation, or if they received blood products or immunosuppressive therapy. Participants were excluded if their mothers (aged ≥18 years) had active tuberculosis disease, diabetes, a history of immunodeficiency except for HIV, hepatitis B or syphilis seropositivity, received blood products in the preceding 6 months, any acute infectious disease, or any suspected substance abuse. Participants were randomly assigned to VPM1002 or BCG vaccination in a 3:1 ratio, stratified by HIV status using the random number generator function in SAS, using a block size of eight paticipants. The primary outcome was non-inferiority (margin 15%) of VPM1002 to BCG vaccine in terms of incidence of grade 3-4 adverse drug reactions or ipsilateral or generalised lymphadenopathy of 10 mm or greater in diameter by 12 months. The primary outcome was assessed in all vaccinated participants (safety population) at regular follow-up visits until 12 months after vaccination. Secondary immunogenicity outcomes were interferon-γ levels and percentages of multifunctional CD4+ and CD8+ T cells among all lymphocytes across the 12 month study period. The study was registered with ClinicalTrials.gov, NCT02391415. FINDINGS: Between June 4, 2015 and Oct 16, 2017, 416 eligible newborn babies were randomly assigned and received study vaccine. Seven (2%) of 312 participants in the VPM1002 group had a grade 3-4 vaccine-related adverse reaction or lymphadenopathy of 10 mm or greater in diameter compared with 34 (33%) of 104 participants in the BCG group (risk difference -30·45% [95% CI -39·61% to -21·28%]; pnon-inferiority<0·0001); VPM1002 was thus non-inferior to BCG for the primary outcome. Incidence of severe injection site reactions was lower with VPM1002 than BCG: scarring occurred in 65 (21%) participants in the VPM1002 group versus 77 (74%) participants in the BCG group (p<0·0001); ulceration occurred in one (<1%) versus 15 (14%; p<0·0001); and abscess formation occurred in five (2%) versus 23 (22%; p<0·0001). Restimulated IFNγ concentrations were lower in the VPM1002 group than the BCG group at week 6, week 12, month 6, and month 12. The percentage of multifunctional CD4+ T cells was higher in the VPM1002 group than the BCG group at day 14 but lower at week 6, week 12, month 6, and month 12. The percentage of multifunctional CD8+ T cells was lower in the VPM1002 group than the BCG group at week 6, week 12, and month 6, but did not differ at other timepoints. INTERPRETATION: VPM1002 was less reactogenic than BCG and was not associated with any serious safety concern. Both vaccines were immunogenic, although responses were higher with the BCG vaccine. VPM1002 is currently being studied for efficacy and safety in a multicentric phase 3 clinical trial in babies in sub-Saharan Africa. FUNDING: Serum Institute of India.
引用
- Cotton MF, Madhi SA, Luabeya AK, et al. Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. Lancet Infect Dis. 2022. PMID: 35772447. doi:10.1016/S1473-3099(22)00222-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。